Mebeverine: Indications and Dosing
Mebeverine is indicated as an antispasmodic agent for symptomatic treatment of abdominal pain and intestinal spasms in irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The medication functions as a direct smooth muscle relaxant without anticholinergic effects 1.
Primary Indication
Mebeverine is specifically used for:
- Irritable bowel syndrome (IBS) - all subtypes including IBS-D (diarrhea predominant)
- Functional abdominal pain related to intestinal smooth muscle spasms
- Spasmodic gastrointestinal disorders
The drug works through direct calcium channel inhibition in gastrointestinal smooth muscle, providing relief from spasmodic pain without central anticholinergic side effects 2.
Adult Dosing
Standard Formulations
For immediate-release tablets (135 mg):
- Dose: 135 mg three times daily
- Taken before meals
For controlled-release capsules (200 mg):
- Dose: 200 mg twice daily
- Superior convenience with equivalent efficacy to the three-times-daily regimen
The 200 mg controlled-release formulation has been proven therapeutically equivalent to the 135 mg three-times-daily tablets, with 70-71% of patients classified as responders in clinical trials 3. The twice-daily dosing offers improved adherence while maintaining comparable efficacy for abdominal pain relief 4.
Treatment Duration
- Initial trial: 4-8 weeks to assess response
- May continue for chronic symptom management as needed
- Response typically defined as ≥50% improvement in abdominal pain severity 3
Pediatric Dosing
For children aged 6-18 years:
- Dose: 135 mg twice daily
- Treatment duration: 4 weeks initially, with follow-up to 12 weeks
In a randomized controlled trial of 115 children with functional abdominal pain, mebeverine 135 mg twice daily showed a response rate of 54.5% at 4 weeks and 72.7% at 12 weeks, though statistical significance over placebo was not achieved 5. Despite modest evidence, this remains the established pediatric dosing when treatment is selected.
Clinical Efficacy Considerations
Evidence Quality
The evidence for mebeverine's efficacy is mixed:
- Abdominal pain relief: Six studies showed significant improvement (p<0.05 to p<0.001) 4
- Global improvement: Meta-analysis showed pooled relative risk of 1.13 (95% CI: 0.59-2.16, p=0.7056) - not statistically significant 6
- IBS-D specific: Modest but statistically significant improvement in bowel movements and cramps, though intergroup differences versus placebo were not significant 7
Practical Application
Despite variable statistical significance in meta-analyses, mebeverine demonstrates:
- Good safety profile with minimal adverse events
- Well-tolerated with adverse events mainly related to underlying IBS symptoms
- Improvements in abdominal distension, stool frequency, and consistency in multiple studies 4
Safety Profile
Common adverse events (rare):
- Constipation (2-6% of patients)
- Abdominal distention (approximately 4%)
The medication is generally well-tolerated with no significant safety concerns identified across multiple trials 3, 4.
Important Clinical Caveats
- Mebeverine may not significantly outperform placebo in severe IBS-D symptoms 7
- The 200 mg controlled-release formulation requires protection from gastric acidity for optimal intestinal delivery 2
- Response rates improve with longer treatment duration (higher at 12 weeks versus 4 weeks) 5
- Neither 135 mg nor 200 mg formulations show significant dose-response differences for efficacy 6